Campylobacterantimicrobial resistance in Peru: a ten-year observational study by Simon Pollett et al.
RESEARCH ARTICLE Open Access
Campylobacter antimicrobial resistance in Peru: a
ten-year observational study
Simon Pollett1*, Claudio Rocha1, Rito Zerpa2, Lilian Patiño2, Augusto Valencia3, Máximo Camiña4, José Guevara5,
Martha Lopez6, Nancy Chuquiray7, Eduardo Salazar-Lindo8, Carlos Calampa9, Martín Casapia10, Rina Meza1,
Maruja Bernal1, Drake Tilley1, Michael Gregory1, Ryan Maves1, Eric Hall1, Franca Jones1, C Sofia Arriola11,
Marieke Rosenbaum1, Juan Perez1 and Matthew Kasper1
Abstract
Background: Campylobacter jejuni and Campylobacter coli are food-borne pathogens of great importance and
feature prominently in the etiology of developing world enteritis and travellers’ diarrhoea. Increasing antimicrobial
resistant Campylobacter prevalence has been described globally, yet data from Peru is limited. Our objective was to
describe the prevalence trends of fluoroquinolone and macrolide-resistant C. jejuni and C. coli stool isolates from
three regions in Peru over a ten-year period.
Methods: Surveillance for enteric pathogens was conducted in Lima, Iquitos and Cusco between 2001 and 2010.
Campylobacter stool isolates were tested for susceptibilities to ciprofloxacin, azithromycin and erythromycin.
Susceptibilities were reviewed for 4652 isolates from Lima (n= 3419), Iquitos (n= 625) and Cusco (n= 608).
Results: Comparing the study periods of 2001-2005 and 2006-2010, prevalence of ciprofloxacin-resistant C. jejuni
isolates rose in the study areas of Lima (73.1% to 89.8%, p< 0.001) and Iquitos (24.1% to 48.9%, p< 0.001).
Ciprofloxacin-resistant C. coli rates also increased in Lima (48.1% to 87.4%, p< 0.001) and Cusco (10.0% to 65.9%,
p= 0.005). Small but significant increases in azithromycin-resistant and erythromycin-resistant C. jejuni prevalence
were noted in Iquitos (2.2% to 14.9%, p< 0.001; 3.2% to 14.9%, p= 0.002), and erythromycin-resistant C. coli rates
increased in Lima (0.0% to 5.3%, p= 0.038). The prevalence of C. jejuni isolates resistant to both ciprofloxacin and
azithromycin increased in Iquitos (0.3% to 14.9%, p < 0.001) and Lima (0.3% to 1.6%, p = 0.011), and prevalence of
C. jejuni isolates resistant to both ciprofloxacin and erythromycin rose in Iquitos (0.0% to 14.9%, p < 0.001).
Ciprofloxacin and erythromycin resistant C. coli prevalence increased in Lima (0.0% to 5.3%, p = 0.034).
Conclusions: These results have implications for the empirical management of enterocolitis in Peru. Ongoing
surveillance is essential to guide appropriate antimicrobial use in this setting. Local epidemiological studies to
explore the relationship between increasing antimicrobial resistance and agricultural or human antibiotic use may
be valuable.
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Background
Campylobacter jejuni and Campylobacter coli are food-
borne zoonotic pathogens that play a major role in the
etiology of human bacterial enterocolitis globally [1].
Campylobacter is a notable pathogen in developing-
world childhood gastroenteritis illness [2], immunocom-
promised patients [3] and traveller’s diarrhea [4]. The
spectrum of campylobacteriosis can range from mild to
severe, particularly in the immunosuppressed, and may
be complicated by neurological and rheumatological se-
quelae [1].
Fluoroquinolones, such as ciprofloxacin, and macro-
lides, namely azithromycin and erythromycin, are the
antibiotic agents of choice for campylobacteriosis [1].
Campylobacter resistance to these agents has long been
described, particularly resistance to fluoroquinolones
[5,6]. The genetic determinants of fluoroquinolone re-
sistance are well characterized, with only a single-step
mutation in the gyrA gene required to confer phenotypic
resistance [7]. The last two decades have seen a striking
rise in quinolone resistance in settings as diverse as
North America, Europe, the Middle East, Africa and
Asia [6,8-11]. While quinolone resistance in Latin Amer-
ica is documented, data from Peru is limited [12,13].
The therapeutic implications of quinolone resistance
in campylobacteriosis are significant, as they are widely
used as empirical first-line antimicrobials for childhood,
travel and other febrile gastrointestinal syndromes in
both developed and developing countries, including Peru
[14,15]. Such resistance trends are also concerning as
they may implicate widespread human and animal quin-
olone use in driving escalating resistance [16,17]. Given
such potential clinical and public health issues, compre-
hensive resistance surveillance for this organism is a pri-
ority in this region. The objective of this study was to
describe the trends in fluoroquinolone and macrolide re-




Surveillance for enteric pathogens in Peru was con-
ducted at nine hospital and community medical labora-
tories throughout Lima (Instituto Nacional de Salud del
Niño, Hospital Nacional Docente Madre-Niño, Hospital
de Emergencias Pediátricas, EsSalud Hospital Alberto
Sabogal Sologuren, Laboratorio Gastrolab and Hospital
Nacional Daniel A.Carrion), Cusco (Laboratorio Servisa-
lud) and Iquitos (Hospital Apoyo de Iquitos and Hos-
pital Regional). These laboratories serve three diverse
regions in Peru. Lima is a coastal city with an estimated
population of 8.5 million persons. Cuzco is a regional
center in the Andes with a population of around 1.2 mil-
lion and Iquitos is an isolated urban hub amidst the
Amazon, with some 370,000 residents [18]. Laboratories
in these latter two provincial cities likely serve a signifi-
cant surrounding catchment population. All laboratories
are public, except that in the Cusco study site. Surveil-
lance occurred from January 2001 to December 2010.
Bacterial identification
Isolates identified as Campylobacter spp. from stool at
study sites as part of routine clinical practice were
placed into Cary-Blair transport media and stored at 4°C
at the study site. Every fifteen days, isolates from each
study site were transported to the U.S Naval Medical Re-
search Unit-6 (NAMRU-6) laboratory at 4°C for con-
firmation of identification, speciation and antimicrobial
susceptibility testing. Bacterial isolates received from
study sites were re-cultured and re-isolated according to
methods described elsewhere [19,20]. Briefly, Campylo-
bacter blood-free selective agar media with ECR 0155
supplement (Oxoid, Cambridge, UK) were inoculated
and incubated in a microaerophilic environment with a
gas mixture of 10% CO2, 5% O2, and 85% N2 in anaer-
obic jars at 42°C for 24 to 48 hours. Campylobacter
jejuni was differentiated from other Campylobacter spe-
cies, including C. coli, by hippurate hydrolysis assay.
Antimicrobial susceptibility testing
Antimicrobial susceptibility disk diffusion testing with
ciprofloxacin, azithromycin and erythromycin was per-
formed according to CLSI guidelines, with disk diffusion
zones for all isolates interpreted as per the most recent
edition of these guidelines [20]. A stock Staphylococcus
aureus strain ATCCW25923 (ATCC, Virginia, USA) cul-
tured on Mueller Hinton Agar (Oxoid, Cambridge, UK)
at 35°C to 37°C was used as a control for susceptibilities
testing conditions. Resistance prevalence was compared
between the two time periods of 2001 to 2005 and 2006
to 2010 using a Chi-square or Fisher’s exact test (Statis-
tical Package for the Social Sciences, Version 17.0, New
York, USA).
Ethical considerations
The testing of these bacterial isolates was determined
not to be human subjects research by the Institutional
Review Board of NAMRU-6.
Results
Susceptibilities were reviewed for a total of 4652 non-
duplicate isolates from Lima (n = 3419), Iquitos (n = 625)
and Cuzco (n = 608). Of all isolates, 82.9% (3856/4652)
were identified as C. jejuni, followed by C. coli (11.9%,
554/4652) and other related or non-identified species
(7%, 242/4652), including C. lari and C. laridis. Preva-
lence trends of antimicrobial resistance to ciprofloxacin,
azithromycin and erythromycin by time and region in C.
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jejuni and C. coli isolates are summarised in Table 1 and
Table 2 respectively.
Between 2001-2005 and 2006-2010, significant changes
in fluoroquinolone-resistant C. jejuni prevalence were
noted in the Lima and Iquitos regions (Table 1). Signifi-
cant changes in ciprofloxacin-resistance rates between
2001-2005 and 2006-2010 were observed in C. coli iso-
lates from both Lima and Cusco (Table 2). Most strik-
ingly, the prevalence of ciprofloxacin-resistant C. jejuni
isolates from Lima rose from 42.1% in 2001 (24/57) to
91.1% in 2010 (319/348, p < 0.001).
There was no significant change in macrolide resist-
ance in C. jejuni either in the Lima or the Cusco regions
between the periods of 2001-2005 and 2006-2010
(Table 1). However, statistically significant increases in
Campylobacter jejuni resistance to the macrolides azi-
thromycin and erythromycin were seen in the Iquitos re-
gion (Table 1). In Lima, a statistically significant rise in
erythromycin-resistant C. coli isolates was seen over the
same time period (Table 2).
The prevalence of C. jejuni and C. coli isolates resist-
ant to both quinolones and macrolides was also com-
pared between the two study periods, and are presented
in Table 3 and Table 4 respectively. Statistically signifi-
cant increases in the prevalence of multidrug-resistant
C.jejuni were noted in Iquitos and Lima, and the preva-
lence of multidrug-resistant C. coli increased in Lima.
Discussion
The significant increase in fluoroquinolone-resistant
Campylobacter prevalence described here reflects similar
trends noted in both the developed and developing
world over the last two decades [5,6]. These findings are
supported by recent but limited data from Peru which
show a comparatively high prevalence (63-78%) [12]. Re-
sistance rates in other South American countries vary
from 14% to 72% [12,13,21,22]. Resistance elsewhere in
the world is also variable, with rates as high as 29% in
Africa, 41% in North America, 80% in Europe, and 93-
100% in Asia [6,8-10,23].
Fluoroquinolone resistance in Campylobacter species
is primarily mediated by mutations in gyrA, a gene
which expresses DNA gyrase, the target of quinolones
[7]. Phenotypic resistance requires a one-step mutation
only [7], and therapeutic use of fluoroquinolone antibio-
tics has been shown to be associated with subsequent
isolation of quinolone-resistant Campylobacter in
humans [16,17,24,25]. As such, the widespread human
use of fluoroquinolones may at least partly contribute to
emerging quinolone resistance [16,17,24].
Human quinolone use may be a factor in the trends
described here. Fluoroquinolones are frequently used in
Peru, with ciprofloxacin identified as the most common
antibiotic prescribed in a study evaluating prescribing
practices in an urban outpatient medical centre in Lima
[26]. Whether the very high quinolone resistance preva-
lence noted in Lima reflects a comparatively greater clin-
ical use of ciprofloxacin in this region compared to
others is unclear. Like many other developing countries,
regulation of these and other antibiotics in Peru is lim-
ited [27] and self-medication with antimicrobials in the
Peru community is well recognised [28]. Antibiotics may
be purchased without prescription, with as much as 29%
obtained without medical authorisation [28]. Further-
more, the quality of antibiotic prescription practices in
Peru is variable [26,28].
Fluoroquinolone-resistant Campylobacter have been
isolated in patients with no prior history of quinolone
use [29]. Moreover, humans are not generally a reservoir
of Campylobacter infection for other humans. It has
thus been suggested that there are other causes for rising
resistance [17]. The intensive use of quinolones in the
food animal industry, especially poultry, and transmis-
sion of resistant organisms via the food chain is thought
to be another cause of rising quinolone resistance
[3,5,16,24,30], although the relationship is complex and
causality is difficult to determine [24,31-35]. As such,
agricultural (rather than human) quinolone use may play
a greater role in the development of resistant Campylo-
bacter in humans, particularly as resistance prevalence
increased in many countries only after the introduction





N° Resis % p-value N° Resis % p-value N° Resis % p-value
Cusco 2001-2005 62 0 0.0 1.000 45 72.6 0.051 0 0.0 1.000
2006-2010 465 2 0.4 385 82.8 2 0.4
Iquitos 2001-2005 316 7 2.2 <0.001 76 24.1 <0.001 10 3.2 0.002
2006-2010 47 7 14.9 23 48.9 7 14.9
Lima 2001-2005 644 9 1.4 0.399 471 73.1 <0.001 8 1.2 0.264
2006-2010 2322 45 1.9 2084 89.8 45 1.9
AZM= azithromycin, CIP = ciprofloxacin, E = erythromycin.
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of quinolones into animal use [24]. The World Health
Organisation has called for the restriction of the use of
antimicrobials in agriculture due to concerns of their
role in Campylobacter and other human enteropathogen
resistance [3]. Countries such as the United States have
banned the use of quinolones in poultry for this reason
[10].
It is possible the food chain may contribute to the high
prevalence of resistance described here. Quinolone-
resistant Campylobacter have been isolated from poultry
in Peruvian shanty towns [36], live birds sold in Peruvian
markets [37], and from food animals in neighbouring
Latin American countries [13,27,37,38]. Ciprofloxacin
resistant E. coli has also been isolated from both food
animals and commercial meat samples in Peru [27] (C.S.
Arriola, unpublished data).
Animal antibiotic use is not currently restricted or
prohibited in Peru (C.S.Arriola, personal communica-
tion). It is mandated to register all antibiotics imported
into Peru with the Peruvian National Tax Administration
(known by its Spanish-language acronym ‘SUNAT’), in-
cluding those used in agriculture. Typical agricultural
fluoroquinolones such as enrofloxacin are among such
imported antibiotics [39]. While antibiotics must be
licensed for animal use in Peru with the Peruvian
Agency of Animal Health (known by its Spanish-
language acronym ‘SENASA’) [40], the nature and extent
of their use in food animals is not directly monitored or
measured (C.S.Arriola personal communication). Enro-
floxacin and norfloxacin are known to be used as thera-
peutic and prophylactic antibiotics, respectively, in some
food animals in Peru (C.S.Arriola, personal communica-
tion), although the extent of this practice is unclear. Fur-
ther studies, including detailed surveillance of animal
antibiotic use and measurement of the prevalence of
quinolone-resistant Campylobacter in commercially
raised food animals, would be valuable to assess the role
of the food chain in the development of quinolone-
resistant Campylobacter in this region. Such studies
would be particularly interesting to undertake in the
Lima region, where the prevalence of quinolone resist-
ance increased the most during our study period (42.1%
in 2001 to 91.1% in 2010, p < 0.001) and where food ani-
mals may be more intensively farmed due to a greater
population density.
International travel has also been identified as a risk
factor for clinical isolation of quinolone-resistant Cam-
pylobacter [17,29]. It is unclear what role, if any, this risk
factor plays in this population.
Macrolide resistance in this study was low overall, al-
though a small but significant increase in prevalence of
macrolide-resistance Campylobacter was noted in Iqui-
tos (in the case of C. jejuni) and Lima (in the case of
C. coli). Limited comparative data from Peru quotes a





N° Resis % p-value N° Resis % p-value N° Resis % p-value
Cusco 2001-2005 10 0 0.0 - 1 10.0 0.005 1 10.0 0.196
2006-2010 41 0 0.0 27 65.9 0 0.0
Iquitos 2001-2005 205 2 1.0 1.000 40 19.5 0.686 6 2.9 0.287
2006-2010 10 0 0.0 3 30.0 1 10.0
Lima 2001-2005 81 4 4.9 1.000 39 48.1 <0.001 0 0.0 0.038
2006-2010 207 12 5.8 181 87.4 11 5.3
AZM= azithromycin, CIP = ciprofloxacin, E = erythromycin.
Table 3 Prevalence of multidrug-resistant Campylobacter





N° Resis % p-value N° Resis % p-value
Cusco 2001-2005 62 0 0 0.605 0 0 0.715
2006-2010 465 2 0.4 1 0.2
Iquitos 2001-2005 316 1 0.3 <0.001 0 0 <0.001
2006-2010 47 7 14.9 7 14.9
Lima 2001-2005 644 2 0.3 0.011 5 0.8 0.106
2006-2010 2322 37 1.6 38 1.6
AZM= azithromycin, CIP = ciprofloxacin, E = erythromycin.
Table 4 Prevalence of multidrug-resistant Campylobacter





N° Resis % p-value N° Resis % p-value
Cusco 2001-2005 10 0 0 - 0 0 -
2006-2010 41 0 0 0 0
Iquitos 2001-2005 205 2 1 0.754 2 1 0.754
2006-2010 10 0 0 0 0
Lima 2001-2005 81 2 2.5 0.238 0 0 0.034
2006-2010 207 12 5.8 11 5.3
AZM= azithromycin, CIP = ciprofloxacin, E = erythromycin.
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macrolide-resistant Campylobacter prevalence of 17%
[12]. Literature from other Latin American countries
reports a highly variable prevalence from 0% to 58.6%
[12,13,22,41,42]. Caution is needed when interpreting
these comparative prevalence rates, as many of them
incorporate animal data. The prevalence of macrolide-
resistant Campylobacter is variable but generally
uncommon in many other parts of the world by com-
parison to fluoroquinolones [5,6,21,43,44]. However,
higher rates of resistance have been noted in some
regions including Africa [45], Europe [45] and Austra-
lasia [6,24,45]. Where significant macrolide resistance
exists, it is usually most prevalent in non-jejuni isolates
[6,43,45].
The overall low prevalence of macrolide resistance
seen in Peru and other parts of the world is thought to
reflect a lower mutation rate and a longer requisite
macrolide exposure time needed to develop resistance.
[5]. Macrolides are used less commonly than fluoroqui-
nolones in Peru[26], and this also may account for the
low rates of resistance here, although understanding of
the link between human macrolide use and macrolide
resistance rates is still evolving [24,46]. It is unknown
whether the small increase in prevalence in Lima and
Iquitos over the study period reflects a possible recent
increase in human macrolide use in those study areas.
Like fluoroquinolones, macrolides are used extensively
in food animals in many countries [6,24], including Peru
(C.S.Arriola, unpublished data). The food chain may play
a role in the etiology of human macrolide-resistant
Campylobacter spp, although the strength of the associ-
ation is unclear [24,45]. Macrolide-resistant Campylo-
bacter have been isolated from food animals in countries
within South America and beyond, particularly in swine
[5,6,42]. Whether the rise in prevalence in Lima and
Iquitos reflects animal macrolide use is a question that
requires further study.
Of all the study regions, only Iquitos showed a statisti-
cally significant increase in resistance to all three anti-
biotics studied. The reason for this is unclear. Possible
causes could include an increase in the human or animal
use of all three of these antibiotics in this region over
the study period. Surveillance of medical and agricul-
tural antibiotic usage in this region, and possibly
human-animal strain linkage studies would be needed to
approach this question. We are unaware of any other
factors in particular that may influence enteric organism
antibiotic resistance in the Iquitos region specifically.
These results have significant therapeutic implications
for the empirical management of enterocolitis in Peru, in-
cluding those with a diarrheal syndrome during or after
travel to Peru. Fluoroquinolones are commonly used first-
line as the empirical management of both developing
world childhood dysentery [15] and travellers’ diarrhea
[14]. Given the important role Campylobacter plays in the
etiology of these clinical syndromes, the risk of antibiotic
failure with empirical fluoroquinolone use in these settings
may be significant based on the resistance prevalence we
have described here.
While the absolute number of multidrug-resistant Cam-
pylobacter isolates was low, the increasing prevalence of
Campylobacter spp resistant to both fluoroquinolones and
macrolides in the Lima and Iquitos areas is concerning, as
these are the two classes of antibiotics usually used to treat
campylobacteriosis, with few to no alternative oral thera-
peutic options available should these agents fail [1], par-
ticularly in a developing world setting.
There are several potential limitations in this study. In-
terpretation of resistance trends is limited by the low
surveillance activity and isolate referral rates in some
regions, with a resultant loss of statistical power. How-
ever, analysing the trends by five-year periods allowed us
to observe some statistically significant trends. The
number of referring laboratories increased over time,
and data on patient characteristics such as age, sex,
socioeconomic status, occupation, travel history and
prior antibiotic use was not collected. Changes in the
study population with respect to such variables could
affect resistance prevalence over time. Measuring these
characteristics would be valuable in future studies to as-
sess the generalizability of antimicrobial resistance
trends described here, to explore associations of these
characteristics with Campylobacter resistance, and to
identify sociodemographic or biological predictors of
antimicrobial-resistant Campylobacter. Measurement of
laboratory catchment population size, changes in this
catchment population size, and faecal sample submission
rates would also be valuable in future studies for the in-
terpretation of resistance trends.
New, sensitive and specific molecular techniques for
the identification of Campylobacter species have
emerged and these may be useful for future surveillance
studies [47]. In addition, significant interlaboratory vari-
ation in macrolide susceptibilities have been described,
particularly with non-microdilution methods [20,48].
While we followed CLSI guidelines for the disk-diffusion
method in testing macrolide and fluoroquinolone sus-
ceptibilities, discrepancy between this technique and
reference standard dilutional assays have been described
in a recent study. Confirming all susceptibilities by dilu-
tional assay may be preferable for future antimicrobial
resistance surveillance [20,49].
Conclusions
In conclusion, significant changes in the prevalence of
antibiotic-resistant Campylobacter have been observed in
Peru, most notably with resistance to fluoroquinolones.
Multi-drug resistant Campylobacter appears to be
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emerging in some areas of Peru. This has implications for
the empirical management of diarrheal infections in this
region. Ongoing surveillance of antimicrobial resistance in
all regions is essential to guide appropriate antimicrobial
use. There is a potential link between emerging antimicro-
bial resistance and agricultural antibiotic use, and local
epidemiological studies to explore this relationship would
be valuable. More stringent monitoring and regulation of
human and animal antimicrobial use, particularly quin-
olone use, is warranted in this region.
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